Assembly Biosciences Inc (ASMB) Q2 2017 10-Q Quarterly Earnings

Short answer

Assembly Biosciences Inc (ASMB) filed its Q2 2017 10-Q quarterly report on Aug 9, 2017 for the quarter ended Jun 30, 2017.

AI summary of MD&A and risk factor updates

Collaboration revenue $2.4M, versus $0 in Q2 2016
Operating margin and profitability figures not disclosed; net loss $27.5M for six months
Microbiome research spending $2.9M increase, versus $1.3M for HBV-cure
Operating cash flow $22.6M, versus $16.0M used in H1 2016, driven by $48.1M deferred revenue
Allergan paid $50M upfront; cash expected to fund operations at least twelve months, with additional financing required thereafter

No material-change disclosure or newly added quarterly risk identified in the provided section
Clinical-stage failure risk: ABI-H0731 entered Phase 1b/2a in Q2 2017, while ABI-M101 remained in late nonclinical development
Regulatory compliance risk: healthcare fraud violations could trigger criminal sanctions, civil penalties, and exclusion from Medicare or Medicaid
Operational risk: third-party manufacturers supply ABI-H0731 and ABI-M101 without Assembly-owned manufacturing facilities
Liquidity risk: accumulated deficit $235.8 million and net loss $27.5 million for six months ended June 30, 2017

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Compare quarters, check guidance or see what insiders and funds did around the report.